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In the present review we discuss the potential involvement of adenosinergic signaling, in
particular the role of adenosine receptors, in amyotrophic lateral sclerosis (ALS). Though
the literature on this topic is not abundant, the information so far available on adenosine
receptors in animal models of ALS highlights the interest to continue to explore the
role of these receptors in this neurodegenerative disease. Indeed, all motor neurons
affected in ALS are responsive to adenosine receptor ligands but interestingly, there
are alterations in pre-symptomatic or early symptomatic stages that mirror those in
advanced disease stages. Information starts to emerge pointing toward a beneficial
role of A2A receptors (A2AR), most probably at early disease states, and a detrimental
role of caffeine, in clear contrast with what occurs in other neurodegenerative diseases.
However, some evidence also exists on a beneficial action of A2AR antagonists. It may
happen that there are time windows where A2AR prove beneficial and others where their
blockade is required. Furthermore, the same changes may not occur simultaneously at
the different synapses. In line with this, it is not fully understood if ALS is a dying back
disease or if it propagates in a centrifugal way. It thus seems crucial to understand
how motor neuron dysfunction occurs, how adenosine receptors are involved in those
dysfunctions and whether the early changes in purinergic signaling are compensatory
or triggers for the disease. Getting this information is crucial before starting the design
of purinergic based strategies to halt or delay disease progression.
Keywords: adenosine receptors, amyotrophic lateral sclerosis (ALS), spinal cord motor neurons, neuromuscular
junction, glial cells
INTRODUCTION
In the present review, we will address the potential role of adenosine on amyotrophic lateral
sclerosis (ALS), also known as Lou Gehrig’s disease. This is one of the most devastating
neurodegenerative disorders and is the most common form of Motor Neuron Diseases group.
During ALS progression, both the upper motor neurons (motor neurons in the cortex) and the
lower motor neurons (motor neurons in the spinal cord) degenerate or die. As a consequence
of deficient input from the motor neuron, there is a progressive and terminal atrophy of skeletal
muscles. All muscles under voluntary control are affected, and individuals lose their strength and
the ability to move their arms, legs and body. When diaphragm and the muscles in the chest wall
fail, people lose the ability to breathe without ventilation support (Nichols et al., 2013).
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The incidence of this disease is 2–3/100,000 and the prevalence
4–7/100,000 (Nalini et al., 2008). The onset of symptoms is
predominantly between 55 and 65 years old and the median
survival of ALS patients, after the diagnosis, is 3–5 years;
however, about 10% of the patients survive for 10 or more years
(Wijesekera and Leigh, 2009).
The majority of cases of ALS are sporadic (sALS) (90–95%),
but some cases have a positive familial history (fALS) (5–10%)
(Kiernan et al., 2011). Both forms, sALS and fALS, present
similar pathological and clinical features. In the case of fALS,
the inheritance is autossomal dominant, but the penetrance
is variable. About 20% of fALS are caused by a missense
mutation in SOD1 gene, encoding for the Cu/Zn superoxide
dismutase 1 enzyme. This finding led to the first and most
used rodent model for ALS, the SOD1G93A mouse, which in
the symptomatic phase recapitulate most features of the disease,
including neuromuscular dysfunction (Naumenko et al., 2011).
There is still a debate whether motor neuron degeneration
initially results from failure of enzymatic machinery at the
level of the cell body and proximal parts of the axon that
then propagates in a centrifugal way due to impaired axonal
transport (Braak et al., 2013), or results from an early dysfunction
at the level of the nerve terminals, with consequent synaptic
dysfunction and then progressing in a ‘dying back’ process
(Frey et al., 2000; Dadon-Nachum et al., 2011), or both (Baker,
2014). As pointed out (Dadon-Nachum et al., 2011), if cell
nerve terminal degeneration precedes with axonal and cell body
degeneration, early intervention focusing on motor neurons
terminals could potentially delay or prevent the progressive loss
of motor neurons. A functional study focusing on the activity of
single end-plates demonstrated that neuromuscular transmission
impairment starts long before symptomatic onset (Rocha et al.,
2013). Importantly, in pre-symptomatic SODG92A mice there
are functional hallmarks of dysregulated intraterminal calcium
levels (Rocha et al., 2013) in consonance with the hypothesis
that nerve terminal machinery designed to buffer calcium might
be impaired at very early disease stages. The pathophysiological
alterations at the neuromuscular junction of SODG92A mice
are accompanied with alterations in the activity of adenosine
receptors at the motor nerve terminals in these mice (Nascimento
et al., 2014, 2015).
Mutations in the gene coding for a nuclear protein, TAR DNA-
binding protein-43 are also frequent in fALS (Leblond et al.,
2014). This protein has several functions in regulation of gene
expression, which thus indicates a clear dysfunction at the level
of the neuronal soma in some forms of ALS. ROS induce the
mislocalization of TAR-DNA binding protein 43 (TDP-43) from
the nucleus into the cytoplasm (Ayala et al., 2011), where it
forms aggregates, an early hallmark of ALS (Neumann et al.,
2006; Chou et al., 2018). Cytoplasmic mislocalization of TDP-43
is accompanied by further ROS production and overactivation
AMP kinase (AMPK), an action suppressed by A2AR activation
(Liu et al., 2015a). Importantly, A2AR activation in a TDP-
43Tg mouse model of ALS, improved motor function (Liu
et al., 2015a). Interestingly also, activation of AMPK changed
the location of a mRNA stabilizer in the motor neurons of ALS
patients, in mouse motor neurons, and in a motor neuron cell
line, and this mislocalization was also suppressed by activation
of A2ARs (Liu et al., 2015b). This again reinforces the idea of a
putative neuroprotective role of A2ARs in ALS since impaired
RNA homeostasis is a major pathway for ALS pathogenesis
(Liu et al., 2017).
Mutations in C9ORF72 are also frequently found in fALS
and accounts for 10% of the sporadic cases (DeJesus-Hernandez
et al., 2011; Smith et al., 2013). Motor neurons with C9ORF72
mutations have increased expression and activity of NMDA
receptors and calcium permeable AMPA receptors (Selvaraj et al.,
2018; Shi et al., 2018), known to be targets for adenosine receptor-
mediated modulation (Dias et al., 2012, 2013). No information so
far exists on the possibility that adenosine receptor ligands may
influence motor neuronal survival in this model of ALS.
Being adenosine a ubiquitous neuromodulator, affecting
synaptic transmission at pre- post and non-synaptic levels, having
adenosine receptors not only neuroprotective but also excitotoxic
and neuroinflammatory actions, it is somehow unexpected that
only relatively few studies concentrated their attention on the
influence of adenosine on ALS progression. Evidence so far
available highlights early dysfunctions of neuromodulation by
adenosine and the ability to influence those dysfunctions through
manipulation of adenosine receptors. In this review we will
critically analyze data so far available.
PATHOPHYSIOLOGY OF ALS
ALS is a complex, multifactorial and multi-systemic disease, the
pathophysiological mechanisms of motor neurons degeneration
remaining yet incompletely known. Some of these mechanisms
include RNA dysfunction, protein misfolding and aggregation,
marked neuromuscular junction abnormalities, immune system
deficiency, mitochondrial dysfunction, neuroinflammation,
cytoskeletal derangements, desregulation of growth factors,
oxidative stress, axonal disruption and apoptosis, excitotoxity
(induced by glutamate), activation of nucleases and proteases and
abnormal calcium metabolism (Pasinelli and Brown, 2006; Costa
et al., 2010; Chou et al., 2018). It is becoming clear that ALS is a
disease that involves different cell types and the communication
between them, the damage that occurs in each cell population
contributing to ALS pathogenicity and phenotype, thus to
the progression of the disease (Taylor et al., 2016). Indeed,
non-motor neuron cells, like interneurons, astrocytes, microglia,
Schwann cells, skeletal muscle cells and oligodendrocytes play
a crucial role in motor neuron survival, and their dysfunction
impact upon motor neuron degeneration. In practical terms,
a major problem that is shared with many neurodegenerative
diseases is that when patients are diagnosed, the neuronal
degeneration, in the case of ALS motor neuron degeneration, has
already started and progressed.
Functional and structural changes at the level of the endplate
are major events in ALS. It has now been realized that the
functional changes may precede not only the structural ones
but also the onset of symptoms. Studies conducted in our lab
(Rocha et al., 2013) to investigate transmission at the diaphragm
neuromuscular junction in SOD1G93A mice revealed that the
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during the pre-symptomatic phase there is an enhanced release
of ACh from nerve terminals, as determined by the mean quantal
content of end-plate potentials. Also in these neuromuscular
junctions the frequency of giant miniature endplate potentials
(GMEPPs) was markedly increased, suggesting that the ability of
the nerve terminal machinery to control cytoplasmatic [Ca2+]
is dysregulated. In early symptomatic (defined as moderate
changes performance in the RotaRod test) SOD1G93A mice two
groups of neuromuscular junctions were identified, both of
them co-existing in the same innervated diaphragm (Rocha
et al., 2013): one group, designated as group A (SOD1a group),
presented significant reduction of the mean amplitude of EPP,
a significant reduction of the mean amplitude of MEPPS,
and a slight but not significant reduction of the quantal
content of EPPs. All these changes indicate a predominant
post-synaptic impairment. The frequency of GMEPPs was
significantly reduced in SOD1a neuromuscular junctions, even
as compared with wild type siblings, indicating that presynaptic
calcium dysregulations persisted, though with opposite signal
in pre-symptomatic and in symptomatic mice. The other group
of neuromuscular junctions, designated as group B (SOD1b)
(Rocha et al., 2013) displayed electrophysiological characteristics
somehow in between those of age-matched wild type and pre-
symptomatic mice, being not significantly different from any of
these groups. Summarizing, data suggest (Rocha et al., 2013)
an exacerbated, but already dysregulated, presynaptic activity at
the mice neuromuscular junctions that do not yet display motor
symptoms; once symptoms start to appear some neuromuscular
junctions are already hypofunctional, some others being probably
in a transition between hyper and hypofunction.
Presynaptic facilitation of neuromuscular transmission
preceding motor symptoms was further confirmed in using
a late onset slow progressing disease model, the SOD1G37R
mice (Arbour et al., 2015). A recent study (Arbour et al.,
2017) taking advantage of this late onset slow progressing
disease model, systematically analyzed the changes in synaptic
properties over the course of the disease progression and as
a function of the motor unit type. Indeed, different motor
units have different susceptibility to the disease, and it became
clear the time course and the sequence of events associated
with neuromuscular transmission dysfunction depend on
the motor unit type (Arbour et al., 2017). The slow motor
neurons are those that degenerate later and interestingly, they
display an early and transient increase in the quantal content of
endplate potentials that disappear at disease onset. In contrast,
fast fatigue motor neurons, those that degenerate first, have
reduced quantal content even before disease onset. Somehow
in the between, fatigue resistant motor units only evidence
neuromuscular transmission dysfunction after disease onset
(Arbour et al., 2017). Interestingly only slow-type motor neurons
display intrinsic hyperexcitability in pre-symptomatic mice
(Leroy et al., 2014), pointing toward the possibility that early
intrinsic hyperexcitability does not contribute to motor neuron
degeneration, but rather represents an early compensatory
process. It is worthwhile to note that as previously seen while
using the SOD1G93A mice (Rocha et al., 2013), in SOD1G37R mice
the neuromuscular transmission alterations precede the onset of
motor symptoms, as well as precede motor neuron loss, axonal
degeneration, and NMJ structural changes (Arbour et al., 2017).
It is nowadays clear that motor neuron degeneration in ALS
also involves glial cells, namely astrocytes, oligodendrocytes,
microglia, Schwann Cells and, in the case of the neuromuscular
junction, perisynaptic Schwann cells (PSCs). PSCs have
neuromodulatory properties close to those of astrocytes in
the central nervous system, closely interacting with nerve
terminals. Thus, PSCs respond to ATP and ACh released
during nerve activity, which act through P2Y and muscarinic
ACh receptors (mAChRs) coupled to transient increases in
intracellular calcium concentration, a process that has to be
kept under proper control to keep PSCs competent for their
functions to modulate and to repair neuromuscular transmission
(Son et al., 1996; Georgiou et al., 1999; Feng and Ko, 2008a,b).
Interestingly, PSC of SOD1 mice displayed exacerbated mAChR
responses and exacerbated calcium signaling, which precede
functional and morphological changes at the neuromuscular
junction, suggesting that the impairments of PSC functions may
contribute to NMJ dysfunction and ALS pathogenesis (Arbour
et al., 2015).
At the level of spinal cord and focusing in neuroinflammatory
and cellular intercommunication hallmarks, it has recently
been also shown a clear difference between pre-symptomatic
and symptomatic stages (Cunha et al., 2017). Thus, before
onset of motor symptoms, alterations in both astrocytes and
microglia have been detected in the spinal cord of SOD1G93A
mice, which comprise decreased expression of astrocytic,
microglia, inflammatory and cell communication markers
together with upregulation of a glutamate transporter-1 marker.
In contrast, in the symptomatic stage, increased markers of
inflammation became evident (Cunha et al., 2017). Microglia
activation, suggestive of a switch from M1 to M2-like microglia
subpopulations, have been detected in control cells exposed to
exosomes derived from motor neuron-like cells transfected with
mutant SOD1G93A (Cunha et al., 2017), thus suggesting that
disease progression is promoted by cell to cell communication
events. There is also a growing body of evidence showing
that astrocytes expressing ALS-associated proteins impair motor
neuron survival and potentiate ALS progression (Di Giorgio
et al., 2007; Nagai et al., 2007; Marchetto et al., 2008; Qian et al.,
2017).
Recent attention has been paid to two other ALS-related
dysfunctions, TDP-43 aggregation and C9ORF72 repeated
expansion. Mutations in the gene that codes for TDP-43,
TARDBP, may favor TDP-43 aggregation but phosphorylated
TDP-43 containing aggregates also occur in sALS (Neumann
et al., 2006; Chou et al., 2018). Indeed, TDP-43 aggregates
are found in 97% of ALS cases of diverse etiology and
constitute a major component of protein inclusions in this
disease (Arai et al., 2006; Maekawa et al., 2009). TDP-43 is
a nuclear protein that interacts with RNA molecules and is
involved in a wide variety of relevant cellular pathways related
to RNA and protein homeostasis. TDP-43 C-terminal missense
mutations have been identified in ALS patients, which promote
mislocalization of TDP-43 from the nucleus to the cytoplasm and
lead to neurotoxicity (Gitcho et al., 2008; Nonaka et al., 2009;
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Guo et al., 2011). Oxidative stress and ROS formation also favor
mislocalization of TDP-43, from the nucleus to the cytoplasm
(Ayala et al., 2011), being thus not surprising that SOD mutations
also lead to TDP-43 pathology in mice and humans (Shan et al.,
2009; Pokrishevsky et al., 2012). ROS upregulates AMP kinase
(AMPK) and abnormal AMPK activity has been shown to induce
TDP-43 mislocalization in a motor neuron cell line and in the
spinal cord of ALS patients (Liu et al., 2015a). Interestingly,
mislocalized TDP-43 in the cytoplasm triggers a positive feedback
loop, leading to further ROS production and AMPK activation
(Liu et al., 2015a).
The present understanding of the mechanisms that underlie
motor neuron degeneration associated to expansion of a G4C2
intronic hexanucleotide of the C9ORF72 gene, is scarce. This
mutation is a common cause of fALS but also accounts for
near 10% of sALS cases (DeJesus-Hernandez et al., 2011; Smith
et al., 2013). A recent study has shown that the C9ORF72
mutation is associated with an increase in GluA1 AMPA
receptor subunit expression, functional expression of Ca2+-
permeable AMPA receptors and motor neuron vulnerability to
excitotoxicity (Selvaraj et al., 2018). Interestingly, early intrinsic
hyperexcitability has been detected in mixed cultures of neurons
and glia derived from C9ORF72 repeat expansion patient iPSCs
(Wainger et al., 2014), but not in neuronal cultures with negligible
number of glial cells (Selvaraj et al., 2018). Also, conditional
medium from astrocytes expressing mutant SOD1 can induce
motor neuron hyperexcitability (Fritz et al., 2013). Altogether
these studies reinforce the idea that diseased astrocytes trigger
excitotoxicity.
Motor neurons, astrocytes, microglia and perisynaptic
Schwann cells are known to release and respond to purines,
namely ATP and adenosine. Adenosine, by activating membrane
receptors (A1, A2A, A2B, A3), is an endogenous and ubiquitous
modulator of synaptic signaling. Released ATP is a source
for extracellular adenosine, but acts on its own purinergic P2
(P2Y and P2X) receptors. So the challenging question is: How
purinergic receptors affect the motor neurons and how this
impacts in ALS? In this review we will only refer to adenosine
receptors since the putative involvement of ATP receptors in
the pathophysiology of ALS has been matter of a recent review
(Volonté et al., 2016).
ADENOSINE AND ADENOSINE
RECEPTORS
Adenosine is a ubiquitous endogenous neuroprotective agent,
which has a central role as a neuromodulator of synaptic
transmission at the central and peripheral nervous systems,
protecting organs and tissues at both physiological and
pathophysiological conditions. Adenosine exerts its biological
effect via a class of purinergic G protein coupled receptors,
which includes A1R, A2AR, A2BR and A3R, all belonging
to family of receptors named by Burnstock (1976) as P1
purinoceptors (adenosine-sensitive) as opposed to the ATP-
sensitive P2 purinoceptors. The A1R couple to Gi/o proteins,
inhibiting the production of cyclic AMP. The A2A and A2B
receptors couple to Gs, stimulating the production of cyclic AMP,
whereas the A3R may couple to Gi/o or Gq proteins. Adenosine
acts like an extracellular signaling molecule, modulating the
action of several neurotransmitters (Ribeiro et al., 2003).
Adenosine A1R are widely distributed in the brain having
a widely recognized inhibitory action in synaptic transmission
associated to a neuroprotective role, while A2AR have more
restrict localizations, being predominant at the basal ganglia.
However, both receptors are present in the cortex, the A1R being
the predominant in this brain area (Dunwiddie and Masino,
2001; Sebastião and Ribeiro, 2009a). A2AR may exacerbate
excitotoxicity in several brain areas (Ribeiro et al., 2016b) as well
as in motor neurons (Mojsilovic-Petrovic et al., 2006). However,
A2AR are also able to gate the action of neuroprotective molecules
as the neurotrophic factors, a mechanism known to occur in the
brain (Diógenes et al., 2004) as well as in motor neurons (Wiese
et al., 2007). Trophic actions of A2AR in cortical neurons, some
of them being independent of the interplay with neurotrophic
factors, have been recently identified (Ribeiro et al., 2016a).
Expression of A2AR in spinal motor neurons is intense, being
higher than that of A1R (Kaelin-Lang et al., 1999; Ng et al., 2015).
A1R in the spinal cord inhibit excitatory inputs (Deuchars
et al., 2001) whereas A2AR facilitate inhibitory inputs (Brooke
et al., 2004) to sympathetic preganglonic neurons, suggesting that
at least in what concerns autonomic nervous system control, the
opposing actions of A1R and A2AR at the synaptic level may both
contribute to a common outcome – a decrease in preganglionic
neuron activity. The antinociceptic actions of adenosine A1R are
widely known, which involve A1R at the dorsal horn of the spinal
cord. A3R receptors also mediate antinociception through spinal
and supraspinal mechanisms (Little et al., 2015) that also involve
anti-inflammation (Janes et al., 2015).
Concerning motor pattern generation, it has been for a long
time described that ATP and adenosine have opposite actions in
motor pattern generation, the adenosine actions being inhibitory,
lowering the excitability of motor circuits (Dale and Gilday,
1996). Recent studies have shown that adenosine, via A1R, has
a general inhibitory action on ventral horn interneurons while
potentially maintaining motor neuron excitability (Witts et al.,
2015). Interestingly, glial cells are a predominant source of
adenosine at to control motor neuron networks at the spinal cord
(Witts et al., 2012; Carlsen and Perrier, 2014; Acton and Miles,
2015).
The motor nerve terminals at the neuromuscular junction
have served as a model to the pioneer studies on the
inhibitory action of adenosine and ATP on neurotransmitter
release (Ginsborg and Hirst, 1972; Ribeiro and Walker, 1973,
1975), being now well known that endogenous adenosine
inhibits neuromuscular transmission (Sebastião and Ribeiro,
1985), that ATP is a source of extracellular adenosine at the
endplate (Ribeiro and Sebastião, 1987), and that adenosine
can also be independently released from stimulated motor
nerve endings (Cunha and Sebastião, 1993). Motor nerve
terminals at the mammalian skeletal neuromuscular junction
possess both inhibitory A1R (Sebastião et al., 1990) and
excitatory A2AR (Correia-de-Sá et al., 1991), the A2AR gaining
particular relevance at high frequencies of nerve stimulation
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(Correia-de-Sá et al., 1996). A2B and A3 receptors were also more
recently detected at the mammalian neuromuscular junction
(Garcia et al., 2014).
Adenosine Receptors in Health and
Disease
At physiological conditions, the adenosine exerts its
neuromodulation action by the activation of A1 and A2AR
high affinity receptors (Sebastião and Ribeiro, 2009a), which
mediate dual actions of adenosine both in health and disease
(Fredholm, 2014). At pre-synaptic level, adenosine can inhibit or
facilitate transmitter release through A1R and A2AR respectively;
at post-synaptic level, it can modulate the actions of several
neurotransmitters and it can hyperpolarize or depolarize
neurons. All these receptors can be found in neurons and glia
cells. While the A1R is frequently associated to neuroprotective
actions, which extend to conditions as hyperexcitability,
seizures and ischemia/hypoxia, protecting neurons in response
to excitotoxic injury (Boison, 2016; Cunha, 2016; Ribeiro
et al., 2016b), the A2AR is often associated to enhancement
of excitotoxicity, since these receptors facilitate glutamate
release and inhibit glutamate uptake (Popoli et al., 2003; Matos
et al., 2012). However, through their ability to gate the actions
of neurotrophic factors, A2AR may confer a protective role
under specific pathologic conditions (Sebastião and Ribeiro,
2009b; Rodrigues et al., 2014). A1R, A2AR and A2BR can also
influence oxygen deliver into the brain due to their influence in
neurovascular coupling (Pelligrino et al., 2010).
Concerning inflammation, A2AR have a duality of actions,
depending on the cell type and inflammatory conditions (Haskó
et al., 2008). In immune cells the global trend for A2AR-
mediated actions is to interrupt the proinflammatory cascade
and hence limiting tissue inflammation (Sitkovsky et al., 2004;
Haskó et al., 2008), contrasting with A2B receptors that may
promote overproduction of proinflammatory cytokines (Haskó
et al., 2008). In the central nervous system, however, A2AR
mediate anti-inflammatory effects on T cells, and thus protection
at early stages of inflammatory diseases; during later stages of
disease, however, may contribute to sustained tissue damage
within the inflamed central nervous system (Ingwersen et al.,
2016). In microglia, A2AR activation leads to their activation, and
in such way contributing to foster neuroinflamatory cascades,
thus to neurodegeneration (Dai and Zhou, 2011; Rebola et al.,
2011; Santiago et al., 2014). Similarly, A2BR and A3R may mediate
either anti-inflammatory or pro-inflammatory actions (Borea
et al., 2017).
Adenosine Receptors in ALS
Adenosine Receptors at Spinal Cord: Implications
for ALS
In accordance with the expected facilitatory influence of
A2AR upon excitotoxicity, A2AR antagonists protect against
excitotoxicity-induced motor neuron death (Mojsilovic-Petrovic
et al., 2006). However, motor neuron survival after mechanical
lesioning has also been shown to be increased by an A2AR
activation, through a mechanism that involves interplay with
neurotrophines (Wiese et al., 2007). Survival of motor neurons
in culture is also facilitated by A2AR activation, this mechanism
requiring the activity of the canonical A2AR signaling pathway,
cyclic AMP/protein kinase activity, as well as the activity
of neurotrophin receptors, again highlighting an interplay
between A2AR and neurotrophins to promote motor neuron
survival (Komaki et al., 2012). The apparent discrepancies
between the neuroprotective actions of A2AR antagonists
and A2AR agonists probably result from the diversity of
actions that the A2AR have, namely modulation of neuronal
activity, neuronal survival, excitotoxicity, neuroinflammation.
While facilitating the actions of neurotrophic factors A2AR
may promote survival and regeneration, but while enhancing
excitotoxicity phenomena A2AR will favor neuronal death.
In addition, if neuroinflammation interferes with in the
regeneration/degeneration balance A2AR may again have a
dual role, depending on the degree and characteristics of
the inflammatory process, that it to say, if activation of the
inflammatory cascade is beneficial or detrimental. Unraveling all
these aspects by taking into consideration the nature of the insult
and the time window for treatment is of uttermost importance to
understand the role of adenosine receptors in neurodegeneration
and in particular in ALS. Our poor understanding of the
pathophysiology of the disease itself makes it more difficult to
understand the role of adenosine receptors in this disease.
Adenosine levels are significantly elevated in the cerebrospinal
fluid of ALS patients (Yoshida et al., 1999), a finding that raised
the interest on the understanding the role of adenosine and
adenosine receptors in ALS. The expression of A2A receptors
is also enhanced in lymphocytes of ALS patients (Vincenzi
et al., 2013) as well as in post-mortem spinal cord of ALS
patients (Ng et al., 2015). A2AR expression in the spinal cord of
early symptomatic SOD1G93A mice was also markedly increased
(Ng et al., 2015), but in end-stage SOD1G93A mice a marked
decrease was reported (Potenza et al., 2013). Mice data thus may
suggest that there is an early enhancement of A2AR expression
in the spinal cord, followed by a decrease in latter disease states.
A comparison of data obtained in the same laboratory conditions
and same animal housing conditions is, however, needed to
firmly conclude on biphasic changes in A2AR expression during
disease progression. Post-mortem human data (Ng et al., 2015),
by definition related to end-stages of the disease, seems to
contradict the conclusion of a late-phase decrease in A2AR
expression in the spinal cord. Whether the discrepancy arrives
from methodological issues (post-mortem time of analysis, tissue
collection procedures), species differences (mice vs. human) or
from inappropriate disease model, is unknown.
Caffeine is a non-selective adenosine receptors antagonist
(Pelligrino et al., 2010; Ribeiro and Sebastião, 2010; Fredholm
et al., 2017) and is one of the most consumable psychoactive
substances of the western diet. There is thus high interest in
understanding the actions of caffeine in neurodegenerative
diseases. Indeed, caffeine consumption in humans has
been negatively associated with the incidence of some
neurodegenerative diseases, as Alzheimer’s Disease and
Parkinson’s Disease (de Mendonça and Cunha, 2010; Flaten et al.,
2014; Laurent et al., 2014; Ascherio and Schwarzschild, 2016).
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Accordingly, chronic caffeine consumption has been shown
to protect several hallmarks of neurodegeneration in animal
models of disease, these actions being frequently mimicked
by selective A2AR antagonists or A2AR deletion (Canas et al.,
2009; Kachroo and Schwarzschild, 2012; Laurent et al., 2016;
Ferreira et al., 2017). Concerning ALS, however, conflicting data
had recently emerged in the literature, and there are several
points that are far from being understood. In clear contrast
to what could be expected from previous evidence in other
neurodegenerative diseases, chronic administration of caffeine
significantly shortens the survival of SOD1G93A mice (Potenza
et al., 2013). Also somehow unexpected, chronic administration
of caffeine caused a marked decrease in A2AR levels in the
spinal cord (Potenza et al., 2013) and in this aspect seems to
mimic the disease itself since SOD1G93A mice also displayed a
strong reduction in A2AR in the spinal cord. Both conditions
(caffeine treatment and SODG93A mutation) were not additive
since there were no further reduction in spinal cord A2AR
levels in SOD1G93A mice treated with caffeine (Potenza et al.,
2013). Caffeine can inhibit all adenosine receptors, and thus
one cannot preclude that those actions of caffeine were due
to antagonism of the usually neuroprotective A1R rather than
antagonism of the A2AR. Indeed, A1 and A2AR are known to
strongly interact with each other (Ferre et al., 2008), including
in motor neurons (Pousinha et al., 2010, 2012), and the loss
of inhibitory control of A1R upon A2AR may cause marked
unbalance of the fine-tuning of neuronal function exerted by
adenosine receptors. A selective A2AR antagonist, KW6002,
administered daily, was recently reported to increase of motor
neuron survival, delay the onset of disease and increase in
the lifespan that SOD1G93A mice (Ng et al., 2015), which is in
accordance with the usual finding that A2AR may exacerbate
excitotoxicity.
Concerning the influence of A2AR agonists in ALS
progression, it has been shown that treatment of SOD1G93A
mice with CGS21680 at a very early symptomatic stage of the
disease, delayed disease onset of motor symptoms and enhanced
motor neuron survival (Yanpallewar et al., 2012). Interestingly,
the effect of the A2AR agonist was similar to that resulting from
genetic deletion of the truncated form of the TrkB receptor,
TrkB.T1, which is overexpressed in the spinal cord of the
SOD1G93A mice. The TrkB.T1 act as negative regulator of full-
length TrkB receptor signaling, impairing the ability of its ligand,
the neurotrophin Brain Derived Neurotrophic factor (BDNF), to
promote neuronal survival, neuronal maturation and neuronal
plasticity. Most of the actions of BDNF at synapses are triggered
by A2AR activation (Diógenes et al., 2004; Sebastião et al., 2011;
Ribeiro et al., 2016b). It is thus likely that the protective influence
of A2AR receptor agonist in very early stages of ALS progression
in SODG93A mice results from the ability of A2AR to facilitate
full length TrkB receptor activation, thus compensating the
negative influence the TrkB.T1 receptor overexpression. That
A2AR and A2AR antagonists may have strict time windows to
exert its beneficial influences in neurodegeneration has been
already proposed (Sebastião and Ribeiro, 2009b) but data from
experiments specifically addressing this point have not yet
appeared.
Also particularly relevant in the context of understanding the
role of A2AR in ALS progression was the finding that A2AR
activation, through PKA signaling, suppresses aberrant AMPK
activity as well as suppresses mislocalization of TDP-43, in the
TDP-43 mouse model of ALS (Liu et al., 2015a). Taking into
consideration that mislocalization of TDP-43 from the nucleus to
the cytoplasm can be induced not only by mutations in the gene
that codes for TDP-43 but also by ROS production, there is some
overlap in the disease triggering mechanisms in the SOD mouse
models and in the TDP-43 model.
Summarizing, in two models of ALS (SOD1G93A and TDP-
43), two different A2AR agonists proved beneficial to improve
motor neuron survival (Yanpallewar et al., 2012; Liu et al., 2015a).
One study clearly showed detrimental effects of the adenosine
receptor antagonist, caffeine in the survival of SOD1G93A mice
(Potenza et al., 2013). Thus, as whole and in the specific context
of ALS, A2AR activation seems beneficial. Importantly, A2AR,
through cAMP/PKA signaling and subsequent inhibition of
AMPK may contribute to cut the positive feedback mechanism
where AMPK activation by ROS leads to further mislocalization
of TDP-43, which leads to further ROS production, thus to
further AMPK activation. In this way, A2AR activation may hit
a key pathophysiologic mechanism of ALS, thus reducing or
even halting disease progression. Unfortunately, in the study
by Liu et al. (2015a), the influence of A2AR activation in the
time of appearance of first symptoms or in the life-span of ALS
mice was not assessed. Results from such studies would indeed
complement the evidence already obtained on enhancement of
motor neuron survival by A2AR activation in two models of ALS
(Yanpallewar et al., 2012; Liu et al., 2015a). Also, and taking into
consideration that the agonist used by Liu et al. (2015a) already
entered clinical trials for other neurodegenerative diseases, a
clinical trial specifically designed for a fast devastating disease as
ALS, would be of high relevance.
A2AR and D2 dopamine receptors (D2R) co-exist in motor
neurons of the spinal cord of normal subjects and ALS patients
(Chern et al., 2017). Activation of D2R reverse the A2AR-
mediated prevention of ROS-induced AMPK activation and
TDP-43 mislocalization in cells co-transfected with D2R and
A2AR (Chern et al., 2017). A2A/D2 negative interactions are well
known in the basal ganglia (Fuxe et al., 2007). The evidence that
they also exist at the level of the spinal cord and in a context of
ALS pathophysiology (Chern et al., 2017), point toward the need
of care in the use of D2R agonists in ALS patients, as well as may
suggest a beneficial role of D2R antagonists in this disease.
From the studies mentioned above, it appears that A2AR
agonists may prove of therapeutic value in ALS. Yet, there
are several discrepancies in the literature, as the report that a
selective A2AR antagonist may delay disease progression. To solve
some discrepancies, it will be important to compare in the same
colony and under the same experimental conditions, and always
against age-matched control littermates, time-dependent and
disease state-dependent changes in the activity and expression
of adenosine receptors. The comparisons among different mouse
models are also of uttermost importance to allow starting to
understand the different roles of A2AR as a function of the
etiology of the disease itself. It will be also necessary to follow
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those changes in mice treated with either selective receptor
ligands as well as with caffeine. Since ALS progression may not be
similar at different synaptic levels, a better understanding of the
time-dependent changes in A2AR signaling at upper and lower
motor neuron levels would also allow a better understanding in
the role of A2AR in ALS. Information of the role of A1R in this
neurodegenerative disease is scarce, which is somehow surprising
on the light of the known neuroprotection exerted by these
receptors. Their ability to inhibit synaptic transmission, may,
however, exert a negative influence in a degenerative disease that
markedly compromises information flow in the motor circuit.
Adenosine Receptors at the Neuromuscular Junction:
Implications for ALS
The neuromuscular junction early served as a model to
understand synaptic transmission mechanisms (Katz and Miledi,
1965), as model to understand neuromodulation by adenosine
(Ginsborg and Hirst, 1972), as a model to understand
the relevance of endogenous adenosine to control synaptic
transmission (Ribeiro and Sebastião, 1987), and as a model to
start identifying A2AR at synapses outside the basal ganglia
(Correia-de-Sá et al., 1991; Correia-de-Sá and Ribeiro, 1994).
Reasons for this are the simplicity of the model, allowing
to record from a single synapse receiving input from only
one nerve terminal, with a clearly identified neurotransmitter
- acetylcholine. In spite of this simplicity, there are several
neuromodulators released by either the pre-synaptic, the post-
synaptic, the muscle itself and the perisynaptic Schwann
cells, which finely tune synaptic transmission and synaptic
maintenance. As widely known, ATP and adenosine are among
such neuromodulators. Neurotrophic factors are also present at
the neuromuscular junction and A2AR are also indispensable
promoters of the facilitatory action BDNF, upon neuromuscular
transmission (Pousinha et al., 2006), as it was firstly observed
hippocampal synapses (Diógenes et al., 2004).
Having studied the action of adenosine for more than 40 years,
using the neuromuscular junction as a model, and considering
that this simple synaptic model could be as a sort of key
(Arbour et al., 2017) to investigate novel approaches for disease
therapy, and also that this particular synapse is compromised
in ALS, we hypothesized (Nascimento et al., 2014, 2015) that
ALS progression could be accompanied by changes in the
functioning of adenosine A1R and A2AR, the two high affinity
adenosine receptors known to be expressed at motor nerve
endings (Correia-de-Sá and Ribeiro, 1994). We used a functional
approach, recording endplate potentials (EPPs) and miniature
endplate potentials (MEPPs), and quantifying quantal content
of EPPs, from Mg2+-paralyzed hemidiaphragm preparations
of SOD1G93A mice at pre-symptomatic (absence of motor
symptoms assessed by the Rota-Rod) and early symptomatic
(mild but significant dysfunction at the Rota-Rod) phases of
the disease. We found that at the pre-symptomatic stage the
A2AR-mediated presynaptic facilitatory action on neuromuscular
transmission is exacerbated, whereas in the early symptomatic
phase, this excitatory action disappears, indicating that indeed
that A2AR function changes upon ALS progression. We then
further investigated the role of A1R in ALS using the same
approach and the same disease model (Nascimento et al., 2015)
and found that the A1R/A2AR functional cross-talk is lost in the
pre-symptomatic phase, so that the ability of A1R to brake the
action of A2AR is lost, which might explain the exacerbation of
the A2AR signaling at this disease state. In addition, there was
an increase of A1R tonic activation in the symptomatic phase,
suggesting that the changes adenosine modulation mediated by
A1R may be contributing to disease progression and aggravating
symptoms in late disease stage. Whether the lack of A1R-
mediated inhibition of A2AR function, with the corresponding
exacerbation of A2AR-mediated function, corresponds to an
early compensatory process that may facilitate neuromuscular
transmission and confer some neuroprotection through an
enhancement of the action of neurotrophic factors, remains
unknown. Also unknown is if these early excitatory changes,
accompanied by dysruptions of the calcium buffering at the nerve
terminal (Rocha et al., 2013) and at perisynaptic Schwann Cells
(Arbour et al., 2015), are a fast-track to neurodegeneration.
Summarizing, data (Nascimento et al., 2014, 2015) suggest that
in ALS there is an unbalanced adenosine receptors modulation at
the neuromuscular junction (Figure 1) that may start before first
signs of motor impairment. We anticipate early compensatory
alterations followed by a disruption of neuromodulatory control
that may then act as an aggravating factor to exacerbate
excitotoxicity, fasting neuronal death. A clear identification of the
nature of these adenosine receptors changes, at different diseases
states, would allow to identify new therapeutic targets based on
the cause of neurodegeneration and thus to halt it.
Interestingly, adenosine A1R at motor nerve endings, besides
inhibiting the release probability, also synchronize release by
removing quantal events with long latencies, an action that is
sensitive to the redox potential, being abolished by oxidants
(Tsentsevitsky et al., 2013). How this impacts in oxidative-stress
related motor neuron diseases, as ALS, is yet unknown.
CONCLUSION AND PERSPECTIVES
A major finding in what concerns adenosinergic signaling in
ALS is the existence of very early synaptic alterations, which
precede motor symptoms and which are evident at the level of
the neuromuscular junction as well as, most probably, at central
synapses. Whether those changes are triggers for the disease or
represent early compensatory modifications is yet unknown. The
evidence of a positive influence of A2AR agonists and negative
influence of caffeine, may suggest that an early enhancement of
A2AR functioning may represent an endogenous attempt to fight
the disease. The positive influence of a selective A2AR antagonist
may, however, contradict this possibility. A better clarification
of the nature of the purinergic signaling dysfunctions, their
implications and their time-windows, is for sure relevant not
only for a better understanding of the pathophysiology of the
disease and the implications of caffeine intake, but also to
guide the design of putative therapeutic strategies to halt disease
progression. Specifically, it is important to know if the early
exacerbation of A2AR signaling detected at the motor nerve
endings also occurs at central synapses, in particular, at the spinal
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FIGURE 1 | Schematic diagram of the reported changes in adenosine signaling at the neuromuscular junction in an ALS mice model. In wild type (A) neuromuscular
junctions, adenosine activates both inhibitory A1R and excitatory A2AR, modulating acetylcholine release from motor nerve terminals. In ALS mice at the
pre-symptomatic stage (B) there is a loss of A1R/A2AR functional cross-talk at the neuromuscular junction and the excitatory action of A2AR is exacerbated. At the
symptomatic stage (C) there is an increase of A1R tonic activation, which may be contributing to neurotransmission failure on late disease stages, whereas the
excitatory action of A2AR disappears. For details see Nascimento et al. (2014, 2015). Perisynaptic Schwann cells contribute to the pool of ATP at the synaptic cleft
but ATP signaling in these cells seems unchanged in ALS, in contrast with mACh signaling (Arbour et al., 2015). Interestingly, the exacerbated A2AR signaling at the
pre-symptomatic stage correlates with an enhanced release of ACh from nerve terminals and with signs of dysregulated calcium buffering at motor nerve endings
(Rocha et al., 2013; Arbour et al., 2017).
cord and motor cortex, and how selective blockade of these
receptors at different disease states affects disease progression.
Keeping in mind the intriguing data reported while testing the
influence of caffeine in animal models, it is also of uttermost
importance to understand the molecular basis of this action
of caffeine, whether it has an impact in the signaling of other
neuroprotective molecules, or in the signaling mediated by other
adenosine receptors. This knowledge is not only important for
the design of future drugs but also to guide research in patients
since caffeine is present in many widely consumed beverages and
is usually regarded as protective against other neurodegenerative
diseases. Lastly, the putative influence of A2AR and A3R in
the inflammatory cascade associated to ALS has to be better
understood. Indeed, recent studies have demonstrated the
presence of inflammation propagating substrates in the central
nervous system of patients afflicted with ALS (Khalid et al.,
2017). A2AR receptors mediate anti-inflammatory actions and
are up-regulated in lymphocytes from ALS patients(Vincenzi
et al., 2013). The A3R is a promising therapeutic target for
inflammatory diseases (Jacobson et al., 2017) but these receptors
have been mostly disregarded in what concerns ALS.
In conclusion, though one starts to envisage changes in the
adenosinergic system at different stages of ALS progression,
much more needs to be known before understanding the causal
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relationship of those changes and which of them can be
targeted to develop novel therapeutics toward this devastating
disease.
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